Abstract Purpose of Review Inhibition of receptor activator of nuclear factor kappa-B ligand
(RANKL) with denosumab is an effective treatment in a number of conditions including …

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and
microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility …

Atherosclerosis is a complex disease that can lead to life-threatening events, such as
myocardial infarction and ischemic stroke. Despite the severity of this disease, diagnosing …

Background: Invasive dental treatment in patients exposed to antiresorptive and
antiangiogenic drugs can cause medication-related osteonecrosis of the jaw (MRONJ) …

Atherosclerotic plaques present key distinctive features that can provide information on the
quiescent state of the plaque or its early disruption triggering fatal events such as myocardial …

Bisphosphonates (BPs) are medications widely used in clinical practice to treat osteoporosis
and reduce fragility fractures. Its beneficial effects on bone tissue have been consolidated in …

Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by brittle bones and
susceptibility to fractures. Management of OI focuses on minimizing fractures and improving …

Bisphosphonates [BPs] are the mainstay for osteoporosis treatment. They suppress bone
resorption/remodeling, preventing bone loss. However, BPs also suppress the beneficial …

In plant-derived compounds, phytoestrogens are biologically active substances that exhibit
various estrogenic and antiestrogenic effects. With the increasing prevalence of …

I read with interest the article by Coffman et al.(1) on the reversible, low hydroxyapatite
(HAP) binding affinity and high farnesyl pyrophosphate synthase (FPPS) inhibition …